S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
66,000% upside on tiny biotech? (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AI Stock Caught Trading Under Secret Name (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
AI Stock Caught Trading Under Secret Name (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
66,000% upside on tiny biotech? (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AI Stock Caught Trading Under Secret Name (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
AI Stock Caught Trading Under Secret Name (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
66,000% upside on tiny biotech? (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AI Stock Caught Trading Under Secret Name (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
AI Stock Caught Trading Under Secret Name (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
66,000% upside on tiny biotech? (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
AI Stock Caught Trading Under Secret Name (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
AI Stock Caught Trading Under Secret Name (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
NASDAQ:AMLX

Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis

$17.65
-0.89 (-4.80%)
(As of 02/23/2024 08:52 PM ET)
Today's Range
$17.36
$19.24
50-Day Range
$13.81
$18.54
52-Week Range
$11.82
$38.32
Volume
2.22 million shs
Average Volume
1.18 million shs
Market Capitalization
$1.19 billion
P/E Ratio
25.21
Dividend Yield
N/A
Price Target
$38.33

Amylyx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
117.2% Upside
$38.33 Price Target
Short Interest
Healthy
10.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.26mentions of Amylyx Pharmaceuticals in the last 14 days
Based on 37 Articles This Week
Insider Trading
Selling Shares
$185,656 Sold Last Quarter
Proj. Earnings Growth
94.44%
From $0.90 to $1.75 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.70 out of 5 stars

Medical Sector

63rd out of 936 stocks

Pharmaceutical Preparations Industry

22nd out of 422 stocks


AMLX stock logo

About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

AMLX Stock Price History

AMLX Stock News Headlines

3 small-cap biotechs with potential breakthroughs in 2024 (AMLX)
These small-cap biotech stocks feature large addressable markets combined with positive analyst sentiment and potential breakthroughs in 2024.
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Down 5.1%
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
See More Headlines
Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
2/25/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMLX
Fax
N/A
Employees
374
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.33
High Stock Price Target
$48.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+117.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-198,380,000.00
Pretax Margin
1.94%

Debt

Sales & Book Value

Annual Sales
$380.79 million
Book Value
$5.14 per share

Miscellaneous

Free Float
59,551,000
Market Cap
$1.19 billion
Optionable
Optionable
Beta
-0.77
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Joshua B. Cohen (Age 32)
    Co-Founder, Co-CEO & Director
    Comp: $1M
  • Mr. Justin B. Klee (Age 33)
    Co-Founder, Co-CEO & Director
    Comp: $1M
  • Mr. James M. Frates M.B.A. (Age 57)
    Chief Financial Officer
    Comp: $695.12k
  • Ms. Gina M. Mazzariello (Age 53)
    Chief Legal Officer & General Counsel
    Comp: $794.83k
  • Mr. Tom Holmes
    Chief Technical Operations Officer
  • Lindsey Allen
    Head of Investor Relations & Communications
  • Ms. Shauna Horvath
    Head of Global Marketing
  • Ms. Debra L. Canner (Age 65)
    Global Head of Human Resources & CHRO
  • Mr. Chris Aiello
    Head of Canada & GM
  • Mr. Keith White
    Head of Global Market Access














AMLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Amylyx Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMLX shares.
View AMLX analyst ratings
or view top-rated stocks.

What is Amylyx Pharmaceuticals' stock price target for 2024?

6 analysts have issued twelve-month price objectives for Amylyx Pharmaceuticals' stock. Their AMLX share price targets range from $27.00 to $48.00. On average, they predict the company's stock price to reach $38.33 in the next year. This suggests a possible upside of 117.2% from the stock's current price.
View analysts price targets for AMLX
or view top-rated stocks among Wall Street analysts.

How have AMLX shares performed in 2024?

Amylyx Pharmaceuticals' stock was trading at $14.72 at the beginning of 2024. Since then, AMLX stock has increased by 19.9% and is now trading at $17.65.
View the best growth stocks for 2024 here
.

Are investors shorting Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 5,440,000 shares, a drop of 5.1% from the January 15th total of 5,730,000 shares. Based on an average daily trading volume, of 1,390,000 shares, the days-to-cover ratio is presently 3.9 days. Currently, 10.9% of the shares of the company are sold short.
View Amylyx Pharmaceuticals' Short Interest
.

When is Amylyx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our AMLX earnings forecast
.

How were Amylyx Pharmaceuticals' earnings last quarter?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) posted its quarterly earnings results on Thursday, February, 22nd. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.03. The firm had revenue of $108.45 million for the quarter, compared to analyst estimates of $106.40 million. Amylyx Pharmaceuticals had a trailing twelve-month return on equity of 12.77% and a net margin of 12.94%. During the same period in the prior year, the company earned ($0.65) earnings per share.

When did Amylyx Pharmaceuticals IPO?

(AMLX) raised $190 million in an IPO on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share.

Who are Amylyx Pharmaceuticals' major shareholders?

Amylyx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.81%), Point72 Asset Management L.P. (4.07%), Stonepine Capital Management LLC (3.70%), Franklin Resources Inc. (1.96%), Goldman Sachs Group Inc. (1.86%) and Nuveen Asset Management LLC (1.51%). Insiders that own company stock include George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian.
View institutional ownership trends
.

How do I buy shares of Amylyx Pharmaceuticals?

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMLX) was last updated on 2/26/2024 by MarketBeat.com Staff